Maze Therapeutics (MAZE) Misses Q2 EPS by 19c
Tweet
Share
E-mailGet Alerts MAZE Hot Sheet
Join SI Premium – FREE
Maze Therapeutics (NASDAQ: MAZE) reported Q2 EPS of ($0.76), $0.19 worse than the analyst estimate of ($0.57).
For earnings history and earnings-related data on Maze Therapeutics (MAZE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Active options: NVDA TSLA SPCX MU AAPL INTC CRWV
- Active options: META SMCI AMZN NBIS HTZ MSFT GOOGL PLTR AMD NOK IREN ORCL MSTR
- Sea Ltd. (SE) PT Raised to $153 at Morgan Stanley
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
